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Background.T oe v a l u a t et h ee ﬀect of rosiglitazone, fenoﬁbrate, or their combined use on plasma lipids in normoglycemic healthy
adults. Methods and Results. Subjects were randomized in a double-blind fashion to rosiglitazone + placebo, fenoﬁbrate + placebo,
rosiglitazone + fenoﬁbrate, or matching double placebo. The between-group diﬀerence in the change in fasting TG, high-density
lipoprotein cholesterol (HDL-C), LDL-C, and plasma apolipoproteins A-I, A-II, and C-III level were compared after 12 weeks of
treatment. A total of 548 subjects were screened and 41 met the inclusion criteria. After 12 weeks of therapy, the median change in
the triglyceride levels showed a signiﬁcant reduction ranging from 47 to 55mg per deciliter in the fenoﬁbrate only and rosiglita-
zone/fenoﬁbrate groups compared with placebo (P = 0.0496). However, the rosiglitazone only group did not show signiﬁcant
change in triglyceride level. The change in the Apo AII showed increase in all the treatment groups compared with placebo (P =
0.009). There was also signiﬁcant change in the Apo CIII that showed reduction of its level in the fenoﬁbrate only and rosiglita-
zone/fenoﬁbrate groups (P = 0.0003). Conclusion. Rosiglitazone does not appear to modulate hypertriglyceridemia in patients
with elevated triglycerides independent of glucose metabolism.
1.Background
The thiazolidinediones (TZDs), which include troglitazone
(withdrawn by the FDA), rosiglitazone, and pioglitazone,
correct hyperglycemia in diabetic patients by increasing in-
sulin sensitivity in both the liver [1, 2] and skeletal muscles
[3, 4]. The mechanism involved in the plasma lipid and lipo-
protein changes induced by thiazolidinediones (TZDs) re-
mains unclear. It is possible that these agents indirectly alter
plasma lipid and lipoprotein levels indirectly by improving
insulin sensitivity and glycemic control or directly by inﬂu-
encing lipoprotein synthesis and/or catabolism. The intent
of this study is to assess whether rosiglitazone aﬀects lipids
independent of glycemic control by testing the hypothesis
in normoglycemic patients with elevated TG. The presence
of synergistic eﬀect when combined with fenoﬁbrate will be
evaluated as well.
Clinical trials using TZDs in type 2 diabetic subjects have
observed that these agents also favorably impact plasma lipid
and apolipoprotein concentrations. Following eight weeks of
treatment with rosiglitazone (4mg, twice daily) in 243 type 2
diabetic patients, the mean HDL-C increased by 6% and TG
by 2%. The increase in the LDL-C concentration (9%) was
accompanied by a shift in small, dense LDL to large, buoyant
LDL in 52% of the treated subjects. The shift in LDL size oc-
curred independent of a signiﬁcant triglyceride reduction,
whichisincontrasttoseveralstudiesreportingthatincreases
in LDL size are signiﬁcantly correlated with a decrease in
theplasmaconcentrationsoftotalandvery-low-densitylipo-
proteins (VLDL) and triglycerides [5, 6]. The mechanism in-
volved in the plasma lipid and lipoprotein changes induced
byTZDsremainsunclear.Itispossiblethattheseagentsindi-
rectly alter plasma lipid and lipoprotein levels indirectly by
improvinginsulinsensitivityandglycemiccontrolordirectly
by inﬂuencing lipoprotein synthesis and/or catabolism.
Three distinct peroxisome proliferator-activated recep-
tors (PPARs), termed alpha, beta, and gamma, modulate in-
tracellular lipid and glucose metabolism through controlling
gene expression when activated [7]. Activation of PPAR-
alpha leads to decrease production of ApoC-III, which in2 Cholesterol
turn increases the synthesis of lipoprotein lipase, and triglyc-
eride catabolism. Gene expression for the synthesis of ApoA-
I and ApoA-II is also enhanced by activation of PPAR-alpha,
resulting in increase in HDL concentration. Fibric acid deri-
vatives (gemﬁbrozil and fenoﬁbrate) reduce triglycerides and
increaseHDL-CbybindingtothePPAR-alphanuclearrecep-
tor. Theoretically, TZDs given to nondiabetic individuals
should not modulate lipid through its eﬀect on PPAR-gam-
ma, and any change would be anticipated to be due to bind-
ing to PPAR-alpha. Thus, it would result in decrease in the
plasma concentration of ApoC-III and an increase in ApoA-I
andApoA-II,withasubsequentriseinHDL-Candreduction
in triglyceride concentration.
The Rosiglitazone and Fenoﬁbrate Additive Eﬀects on
Lipids (RAFAEL) trial was designed to evaluate the eﬀect of
rosiglitazone when combined with fenoﬁbrate on the plasma
lipid and lipoprotein concentrations assuming direct inﬂu-
ence on the synthesis of the apolipoproteins that are respon-
sible for VLDL and HDL metabolism in normo-glycemic in-
dividualswithelevatedTGaswellasthemechanismofaction
of rosiglitazone.
2. Methods
2.1. Study Protocol and Oversight. The Rosiglitazone and
Fenoﬁbrate Additive Eﬀects on Lipids (RAFAEL) protocol
was reviewed and approved by the institutional review board
at Brooke Army Medical Center where the trial was con-
ducted. The study was sponsored by GlaxoSmithKline (Lon-
don, UK), ClinicalTrials.gov ID: NCT00819910.
2.2. Study Population. All patients provided written infor-
med consent to participate in the study. Patients were eligible
if they were 18 years of age or older, had a fasting glucose
<100mg/dL, fasting LDL-C <160mg/dL, and a triglyceride
<400mg/dL. Patients taking any cholesterol lowering medi-
cation prior to entering the study underwent a “wash-out”
period of two weeks. Patients were excluded if they had a his-
toryofcongestiveheartfailure,evidenceofrenalimpairment
(Cr > 1.4mg/dL), history of liver disease (ALT and/or AST
above the upper level of normal), known diabetes mellitus
or impaired fasting glucose (fasting glucose > 100mg/dL),
pregnantorbreastfeeding,priorhistoryofanacutecoronary
syndrome, myocardial infarction, or coronary revasculariza-
tion, life-threatening disease with an estimated survival of
less than 3 years, or inability to take rosiglitazone and/or fe-
noﬁbrate.
2.3. Study Design. At the beginning of the trial, candidates
were instructed to fast for 12 to 15 hours for the initial
visit. Baseline fasting lipid proﬁle with direct LDL-C mea-
surement, fasting glucose, hepatic function and plasma
concentrations of apolipoproteins A-I, A-II, and C-III were
drawn at the initial visit. Based on the concentration of total
cholesterol, triglyceride, and glucose, eligible subjects were
randomized within 7 days of providing the initial blood
sample. Subjects, who met the inclusion criteria, were then
randomized to one of 4 groups: rosiglitazone (dose 8mg
daily) plus placebo; fenoﬁbrate (145mg daily) plus placebo;
fenoﬁbrate (145mg daily) plus rosiglitazone (dose 8mg
daily); or double placebo for a total of 12 weeks. At the mark
of12weeks(ﬁnalvisit),theinitiallaboratorycollectionswere
repeated to assess the diﬀerence in concentration of fasting
glucose, insulin, hepatic transaminases, fasting lipid proﬁle,
apolipoproteins, HDL size, LDL size, and statistical diﬀer-
ence from baseline. At this visit, subjects were asked to re-
turntheirbottlesforapillcounttoassesscomplianceandas-
sessment of adverse events was done at this time. All blood
samples were shipped to Oklahoma Research Foundation
for apolipoproteins A-I, A-II, and C-III assessments and the
remainderofthelabswereshippedtoQuestDiagnosticLabs.
2.4. End Points. The primary end-point with respect to eﬃ-
cacy was the between-group diﬀerence in the change in TG
levels after 12 weeks of treatment. Secondary end-points
included the between-group diﬀerence in the change in
HDL-C, LDL-C, Apo AI, Apo AII, and Apo CIII levels. The
primary safety end-point was the incidence of elevations in
AST and ALT, deﬁned as more than three times the upper
limit of normal.
2.5. Statistical Analysis. The null hypothesis was that there
will be no diﬀerence in the serum triglyceride level between
treatments. The alternative hypothesis is that there will be
at least a 20% decrease in the serum triglyceride level in
the fenoﬁbrate, rosiglitazone, fenoﬁbrate, and rosiglitazone
treatment groups relative to the placebo group.
The sample size was determined to be 16 subjects in each
arm (64 subjects total) based on eight comparisons between
groups before and after treatment with 80% power and a
95% level of conﬁdence. Anticipating a 25% drop out rate,
aimed for 20 subjects per group for a total of 80 subjects, but
we were only able to recruit 41 subjects due restrictions to
the prescriptive pattern with thiazolidinediones per the Food
and Drug Administration that occurred after the start of the
trial. Statistical diﬀerences among the four treatment groups
were assessed by comparing the median changes among
groups using Kruskal-Wallis one-way analysis of variance on
ranks. P values < 0.05 were considered statistically signiﬁ-
cant.
3. Results
Between October 2008 and August 2010, a total of 548
patients were screened at one center. Of the 548 patients
who were screened, a total of 41 patients met the inclusion
criteria and were randomly assigned one of the prespeciﬁed
study groups. As of October 2010, follow-up assessment,
with ascertainment of end points, was completed in 73% of
the patients in the study. There were seven (17%) patients
that did not complete the study due to either lost of followup
or adverse events that make them to withdraw from the
study. The baseline characteristics of the patients who were
enrolled in the study are shown in Table 1. The mean age
was 56 years; 48% of the patients were male, and 39% of
the patients were treated for hypertension. At baseline, the
mean total cholesterol was 214mg per deciliter, mean HDL
cholesterol was 48mg per deciliter, mean LDL cholesterolCholesterol 3
Table 1: Baseline characteristics and laboratory ﬁndings with posttreatment changes.
Group
Placebo Fenoﬁbrate Rosiglitazone Combined ANOVA
N = 10 N = 9 N = 8 N = 7R a n k
Mean ± SD Mean ± SD Mean ± SD Mean ± SD P-value
Age 57.4 ±11.16 1 .2 ±11.65 7 .3 ±8.45 4 .7 ±9.5
M:F 6:4 3:6 5:3 3:4
Pre-TG 206 ±65 278 ±126 234 ±58 239 ±73
P = 0.212 Post-TG 202 ±53 192 ±64 240 ±115 172 ±27
(%Δ)( 7 .6% ± 51.0%) (−2.2% ±26.0%) (7.4% ±48.9%) (20.0% ±36.5%)
Pre-HDL-C 48 ±94 1 ±85 2 ±19 52 ±14
P = 0.342 Post-HDL-C 48 ±94 7 ±75 0 ±17 53 ±9
(%Δ)( 1 .7% ± 10.5%) (14.5% ±21.6%) (1.9% ±24.6%) (5.8% ±16.4%)
Pre-LDL-C 124 ±46 111 ±40 145 ±24.6% 106 ±41
P = 0.692 Post-LDL-C 128 ±39 118 ±32 140 ±41 102 ±31
(%Δ)( 1 3 .7% ±47.8%) (2.6% ±29.3%) (−.5% ±27.4%) (37.3% ±141.6%)
± pre-Tot C 204.4 ±57.9 213.6 ±39.0 238.4 ±39.5 215.7 ±36.6
P = 0.372 Post-Tot C 227.4 ±37.2 199.0 ±51.2 230.9 ±52.2 201.1 ±36.5
(%Δ)( 2 5 .8% ±70.2%) (−7.7% ±26.1%) (−2.3% ±21.3%) (−5.0% ±21.6%)
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Figure 1: Median change in lipid proﬁle after treatment.
was 121mg per deciliter, and mean triglyceride was 240mg
per deciliter.
After 12 weeks of therapy, the change in the triglyceride
levels showed a signiﬁcant reduction ranging from 47 to
55mg per deciliter in the fenoﬁbrate only and rosiglitazone/
fenoﬁbrate groups compared with placebo (P = 0.0496)
(Figure 1). However, the rosiglitazone only group did not
show signiﬁcant change in triglyceride level. There was also a
signiﬁcant reduction in the HDL levels showing a signiﬁcant
reduction ranging from 20 to 22mg per deciliter compared
with placebo (P = 0.0152) (Figure 1). There was no signi-
ﬁcant diﬀerence in the median change in the total cholesterol
or LDL cholesterol between the groups (Figure 1). In regards
to the apolipoproteins, the median change in the Apo AII
showed a signiﬁcant increase in all the treatment groups
compared with placebo (P = 0.009) (Figure 2). There was
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Figure 2:MedianchangebeforeandaftertreatmentinAposubpar-
ticle, blood sugar, and weight.
also signiﬁcant median change in the Apo CIII that showed
reduction of its level in the fenoﬁbrate only and rosiglita-
zone/fenoﬁbrate groups (P = 0.0003) (Figure 2). There was
no diﬀerence in median change in Apo AI (Figure 2).
3.1. Safety End Points. There were adverse events reported
in seventeen patients in the study. Four adverse events led
to discontinuation of therapy in most cases during the
study (three ADE’s in the combined arm and one in the
double placebo arm). There was one patient in the combined
(rosiglitazone and fenoﬁbrate) group who was hospitalized
during the study due to acute renal failure (SAE’s). The most4 Cholesterol
common adverse eﬀects were headache and gastrointestinal
complains such as abdominal discomfort, diarrhea, nausea,
and vomiting. The level of transaminases did not increase
signiﬁcantly in any of the patients in each treatment group.
4. Discussion
Clinical trials have shown that the use of thiazolidinedione
in type 2 diabetic patients has shown favorable impact in
plasma lipid and lipoprotein concentrations in addition to
glycemic control. The mechanism involved in the plasma
lipid and lipoprotein concentration changes in type 2
diabetics by thiazolidinedione remains unclear. The RAFAEL
trial is the ﬁrst study performed in the literature to evaluate
the eﬀect of thiazolidinedione to plasma lipid and apo-
lipoprotein concentration in normoglycemic population to
assess mechanism of action. After 12 weeks of therapy, the
median change in the triglyceride level was only signiﬁcant
in the group that received fenoﬁbrate as expected due to its
knownmechanismofaction.Wealsosawsigniﬁcantchanges
in the fenoﬁbrate/rosiglitazone group which were most likely
due to the fenoﬁbrate alone since it was very similar change
compared to the fenoﬁbrate alone. In addition, the rosig-
litazone group did not show a signiﬁcant change in the tri-
glyceride level. Therefore, combination therapy of rosiglita-
zone and fenoﬁbrate did not show trend towards additive
r e d u c t i o ni nt r i g l y c e r i d el e v e l s .
In regards to the apolipoproteins, all treatment groups
showed signiﬁcant increase in the median change of Apo AII
compared to placebo. Also, median change of Apo CIII
showed signiﬁcant reduction of its level in the fenoﬁbrate
only and fenoﬁbrate/rosiglitazone groups. However, this
change was not seen in the rosiglitazone group only. As a
result, rosiglitazone does not aﬀect Apo CIII levels and sub-
sequently lipoprotein lipase activity as anticipated. However,
rosiglitazone increases Apo AII levels without observed
change in HDL-C in patients with type 4 hyperlipidemia
with normoglycemia. Fibrates impact on TG reduction is
known to correlate with its reduction of Apo CIII in animal
models [8]. The absence of impact on ApoC III and TG
simultaneously by Rosi does not negate the fact that it might
bind to PPAR alpha and therefore aﬀecting ApoAII, but it
negates its independent impact on lipid metabolism as a
PPAR-alpha strong agonist independent of glucose metabo-
lism.
Several limitations of the current study should be con-
sidered. First, the study was terminated early per FDA rec-
ommendations restricting rosiglitazone use. Second, recruit-
ment of patients was slow due to deployment restraints and
thepublicationofvariousstudiesevaluatingthecardiovascu-
lar complications of rosiglitazone. Therefore, the sample size
was insuﬃcient for power analysis, and strength of statistical
signiﬁcance was adversely aﬀected in all end points.
5. Conclusion
In conclusion, the results from our study suggest the favor-
able eﬀects of rosiglitazone on plasma lipid and lipoprotein
concentrations in diabetic patients noted in prior studies are
not independent of glucose control as noted in our normo-
glycemic cohort of subjects.
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